

OncoTherapy Science, Inc.

November 4, 2014

Receipt of a grant for translational research using our compound

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, "OncoTherapy") announces that a group in the University of Chicago has received a grant from The V Foundation for Cancer Research* (North Carolina, U.S.A.) for a translational research using a small molecule compound developed by OncoTherapy. OncoTherapy will provide the compound for the translational research.

This small molecule compound (the compound reported on October 23rd 2014) is a highly potent drug candidate, and inhibits an oncogene product TOPK that has a critical role in cell division of cancer cells. Since this compound has also been shown to be effective to FLT3-mutated AML (Acute Myeloid Leukemia), this translational research aims to perform phase I study for AML patients with FLT3 mutation. It is a first-in-human clinical study using a TOPK inhibitor. The V Foundation for Cancer Research is a charitable organization dedicated to save lives by supporting the discovery of cancer treatment.

* The V Foundation for cancer research

The V Foundation is a charitable organization dedicated to saving lives by helping to find a cure for cancer.

Office: Cary, North Carolina, U.S.A.

Established: in 1993

Founder: ESPN and Jim Valvano

Activity: The V Foundation for Cancer Research has a track record of 540 cases, more than 130 million dollars, more than 120 institutes in 38 states and Washington DC in U. S. A. by the 3 kinds of grants.

Target: Medical doctors and researchers

Category: The V Scholar Grant

The V Foundation Grants in Translational Cancer Research

Designated Grants

Funding: Donation